Trastuzumab, sold under the brand Herceptin, is a monoclonal antibody used for the treatment of breast cancer and gastric cancer. Herceptin is mainly used to treat patients suffering from cancer and diagnosed with HER2 receptor positive. Herceptin mechanism of action is binding itself to HER2 receptors on the surface of breast cancer cells and blocking them from receiving growth signals and thus decreasing the mutation of cells. Herceptin acts as an immune targeted therapy for breast cancer patients.
Product approvals and launches are the factors driving the growth of the global herceptin biosimilar market. For instance, in February 2020, Pfizer Inc., a biotechnology and pharmaceutical company in the U.S., launched the trastuzumab biosimilar, Trazimera, for treatment of human epidermal growth receptor causing breast cancer and metastatic gastric cancer.
- This report provides in-depth analysis of the global herceptin biosimilar market, and provides market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2026–2033), considering 2025 as the base year
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new drug launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global Herceptin biosimilar market based on the following parameters – company overview, financial performance, drugs portfolio, market presence, distribution strategies, key developments, strategies, and future plans
- Key companies covered as a part of this study are Amgen Inc., AryoGen Biopharma, Biocon Limited, Celltrion Inc., Pfizer Inc., Merck & Co., Inc., Accord Healthcare Ltd, Gedeon Richter Plc, Genor Biopharma Company Ltd, Mabion SA, Mylan N.V, Roche Holding AG and Samsungbioepis Co,.Ltd
- Insights from this report would allow marketers and management authorities of companies to make informed decisions regarding future drug launches, drug class up-gradation, market expansion, and marketing tactics
- The global herceptin biosimilar market report caters to various stakeholders in this industry including investors, suppliers, device manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global herceptin biosimilar market.
-
- Breast Cancer
- Gastric Cancer
- Others
-
- Hospitals
- Oncology Centers
- Others
-
- North America
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC
- Israel
- Rest of Middle East
- Africa
- South Africa
- Central Africa
- North Africa
-
- Amgen Inc.
- AryoGen Biopharma
- Biocon Limited
- Celltrion Inc.
- Pfizer Inc.
- Merck & Co., Inc.
- Accord Healthcare Ltd
- Gedeon Richter Plc
- Genor Biopharma Company Ltd
- Mabion SA
- Mylan N.V
- Roche Holding AG
- Samsungbioepis Co., Ltd.
